74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
AbCellera Biologics Inc
Closed
SectorHealthcare
2.59 2.37
Overview
Share price change
24h
Min
2.52
Max
2.59
Income | 17M -34M |
|---|---|
Sales | -1.5M 5.1M |
EPS | -0.12 |
Profit margin | -677.426 |
Employees | 596 |
EBITDA | -3.4M -55M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +350.59% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | 27M 730M |
|---|---|
Previous open | 0.22 |
Previous close | 2.59 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
AbCellera Biologics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
AbCellera Biologics Inc Forecast
Price Target
By TipRanks
350.59% upside
12 Months Forecast
Average 11.4 USD 350.59%
High 28 USD
Low 5 USD
Based on 7 Wall Street analysts offering 12 month price targets forAbCellera Biologics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About AbCellera Biologics Inc
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
